H. Degrendele

发表

Cell-cycle inhibitors as novel therapies for lung cancer.

H. Degrendele, 2002, Clinical lung cancer.

Advances in the use of fecal DNA screening for the detection of colorectal cancer.

E. Chu, H. Degrendele, V. Jain, 2003, Clinical colorectal cancer.

Requirement for CD44 in activated T cell extravasation into an inflammatory site.

H. Degrendele, M. Siegelman, P. Estess, 1997, Science.

Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

H. Degrendele, 2003, Clinical breast cancer.

Gene Expression Patterns in Breast Cancer May Identify Specific Tumor Phenotypes and Predict Disease Outcome

J. O’Shaughnessy, H. Degrendele, V. Jain, 2002 .

2003 Highlights from: 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois May 31 to June 3, 2003

J. O’Shaughnessy, H. Degrendele, P. Tyagi, 2003 .

Assessment of Cognitive Function in Patients Receiving Adjuvant Endocrine Therapy

J. O’Shaughnessy, H. Degrendele, 2003 .

Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois May 31 to June 3, 2003

J. Marshall, E. Chu, H. Degrendele, 2003 .

Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.

R. Schilsky, E. Chu, H. Degrendele, 2002, Clinical colorectal cancer.

The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.

E. Chu, H. Degrendele, V. Jain, 2003, Clinical colorectal cancer.

44th annual meeting of the American Society of Hematology. December 7-10, 2002. Philadelphia, Pennsylvania.

H. Degrendele, Mary Hightower, A. Gibson, 2003, Clinical lymphoma.

Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

H. Degrendele, 2003, Clinical lung cancer.

Highlights from the 98th annual meeting of the American Urological Association Chicago, IL.

H. Degrendele, Mary Hightower, J. Klem, 2003, Clinical prostate cancer.

Update on the Use of Radiopharmaceuticals for the Treatment of Painful Bone Metastases

J. O’Shaughnessy, H. Degrendele, 2003 .

Highlights from: 38th Annual Meeting of the American Society of Clinical Oncology May 18–21, 2002; Orlando, Florida

M. Kaminski, H. Degrendele, J. Lynch, 2002 .

Highlights From: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida May 18–21, 2002

H. Degrendele, Vinay K. Jain, Chandra P. Belani, 2002 .

39th Annual Meeting of the American Society of Clinical Oncology: Chicago, Illinois, May 30 to June 3, 2003.

H. Degrendele, David J. Lee, 2003, Clinical lung cancer.

CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation.

H. Degrendele, M. Siegelman, P. Estess, 1997, Journal of immunology.

Recent Data with Gemcitabine-Based Chemotherapy Combinations in Metastatic Breast Cancer

J. O’Shaughnessy, H. Degrendele, 2003 .

Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity.

H. Degrendele, M. Siegelman, P. Estess, 1998, The Journal of clinical investigation.

The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer.

H. Degrendele, 2003, Clinical prostate cancer.

Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.

J. Marshall, E. Chu, H. Degrendele, 2003, Clinical colorectal cancer.

27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.

H. Degrendele, 2002, Clinical lung cancer.

CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway

L. Picker, H. Degrendele, M. Siegelman, 1996, The Journal of experimental medicine.

Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion.

M. Mohamadzadeh, H. Degrendele, H. Arizpe, 1998, The Journal of clinical investigation.

Activation and interaction of CD44 and hyaluronan in immunological systems

H. Degrendele, M. Siegelman, P. Estess, 1999, Journal of leukocyte biology.

Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.

H. Degrendele, 2003, Clinical prostate cancer.

Current data with bexarotene (Targretin) in non-small-cell lung cancer.

H. Degrendele, 2003, Clinical lung cancer.

2002 Highlights from: 27th European Society of Medical Oncology Congress, Nice, France, October 18–22

H. Degrendele, V. Jain, K. Maung, 2002 .